A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
← catalyst calendarNCT07511205 · readout in 233 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
104estimated
Sites
3
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-30 | actual | When the study began enrolling |
| Primary completion | 2027-04-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-17 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Participants
- Obesity
Interventions
- Drug: AZD1043
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs), serious adverse events (SAEs), AE leading to discontinuation (DAEs), and AEs of special interest (AESIs)
measured Part A (SAD): From Day-35 to Day 253; Part B (MAD): From Day 1 to Day 253
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed